HL161BK

HL161BK is a **full-length humanized monoclonal antibody antagonist of the neonatal Fc receptor (FcRn)**. It binds to human FcRn with high affinity, leading to the rapid downregulation and degradation of FcRn in cells, which in turn lowers the levels of both circulating IgG and albumin. Unlike some other FcRn antagonists, HL161BK also blocks the binding of albumin to FcRn, resulting in a more substantial decrease in both IgG and albumin recycling. This mechanism positions HL161BK as a therapeutic candidate for **IgG-mediated autoimmune disorders**[1][2]. Development and preclinical studies have demonstrated that HL161BK effectively decreases FcRn expression and serum albumin levels in relevant cellular and animal models[1][2].